Goldman Sachs
PRAX icon

Goldman Sachs’s Praxis Precision Medicines PRAX Stock Holding History

Goldman Sachs’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184M Sell
548,830
-161,904
-23% -$51.3M 0.02% 819
2026
Q1 		$229M Sell
710,734
-5,450
-0.8% -$1.69M 0.03% 620
2025
Q4 		$211M Buy
716,184
+123,163
+21% +$22.9M 0.03% 617
2025
Q3 		$31.4M Buy
593,021
+367,029
+162% +$17.8M ﹤0.01% 1825
2025
Q2 		$9.5M Buy
225,992
+48,728
+27% +$1.86M ﹤0.01% 2803
2025
Q1 		$6.71M Sell
177,264
-102,131
-37% -$6.38M ﹤0.01% 3066
2024
Q4 		$21.5M Sell
279,395
-225
-0.1% -$16.3K ﹤0.01% 2059
2024
Q3 		$16.1M Buy
279,620
+148,623
+113% +$8.03M ﹤0.01% 2257
2024
Q2 		$5.42M Buy
130,997
+32,362
+33% +$1.53M ﹤0.01% 3075
2024
Q1 		$6.02M Buy
+98,635
New +$4.43M ﹤0.01% 2926
2023
Q4 		– Sell
-6,174
Closed -$158K – 5791
2023
Q3 		$158K Sell
6,174
-4,061
-40% -$76.8K ﹤0.01% 5099
2023
Q2 		$177K Sell
10,235
-40,477
-80% -$620K ﹤0.01% 5224
2023
Q1 		$615K Buy
50,712
+2,749
+6% +$116K ﹤0.01% 4714
2022
Q4 		$1.71M Sell
47,963
-26,877
-36% -$838K ﹤0.01% 4057
2022
Q3 		$2.55M Buy
74,840
+35,127
+88% +$1.75M ﹤0.01% 3763
2022
Q2 		$1.46M Buy
39,713
+30,410
+327% +$3.25M ﹤0.01% 4317
2022
Q1 		$1.43M Buy
9,303
+4,244
+84% +$872K ﹤0.01% 4541
2021
Q4 		$1.5M Sell
5,059
-2,200
-30% -$645K ﹤0.01% 4502
2021
Q3 		$2.01M Buy
7,259
+1,500
+26% +$407K ﹤0.01% 4191
2021
Q2 		$1.58M Sell
5,759
-886
-13% -$317K ﹤0.01% 4408
2021
Q1 		$3.27M Buy
6,645
+2,263
+52% +$1.61M ﹤0.01% 3520
2020
Q4 		$3.62M Buy
+4,382
New +$2.56M ﹤0.01% 3261

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs's PRAX Position: Q2 2026 in Review

Goldman Sachs reduced its Praxis Precision Medicines (PRAX) stake by 23% in Q2 2026, selling an estimated $51.3M and leaving 548,830 shares worth $184M. The position accounts for 0.02% of the portfolio, ranked #819.

Goldman Sachs first reported a position in PRAX in Q4 2020 and has held it in 22 quarters since. The position peaked at $229M in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Goldman Sachs held 548,830 shares of Praxis Precision Medicines worth $184M as of Q2 2026.
  • Goldman Sachs sold 161,904 Praxis Precision Medicines shares in Q2 2026, an estimated $51.3M.
  • Praxis Precision Medicines made up 0.02% of Goldman Sachs's portfolio in Q2 2026, its #819 holding.
  • Goldman Sachs first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 22 quarters since.
  • Goldman Sachs's Praxis Precision Medicines position peaked at $229M in Q1 2026.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.